Skip to content

Septerna, Inc. SEPN Net Investment in Lease

Net Investment in Lease at other companies

Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
Precigen logo
PrecigenPGEN
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.62B+319%

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Reported directly by Septerna, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Septerna, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s net investment in lease?
Septerna, Inc. (SEPN) reported net investment in lease of $20.93M in Q1 2026.
How has Septerna, Inc.'s net investment in lease changed year-over-year?
Septerna, Inc.'s net investment in lease decreased by 9.3% year-over-year, from $23.09M to $20.93M.
What is the long-term trend for Septerna, Inc.'s net investment in lease?
Over 2 years (2023 to 2025), Septerna, Inc.'s net investment in lease has grown at a 31.0% compound annual growth rate (CAGR), from $12.52M to $21.5M.